TGA – Australia: Independent Expert Panel on MDMA and psilocybin – Systematic literature review of the therapeutic value, benefits and risks of MDMA and psilocybin for the treatment of mental health conditions
Cannabis Law Report
OCTOBER 5, 2021
The Panel’s report will be considered by the Advisory Committee of Medicines Scheduling (ACMS) at the 3 November 2021 meeting. The review excludes pre-clinical trials (i.e. He obtained fellowship of the relevant Colleges in the UK, Australasia and Canada, as well as of the Australasian Chapter of Addiction Medicine.
Let's personalize your content